IQVIA Announces Pricing of Secondary Public Offering
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 6, 2019--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 5,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), at a price to the public of $141.00 per share. IQVIA intends to repurchase from the underwriters 1,000,000 shares (the “Repurchase”).
IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering. IQVIA’s per-share purchase price for the repurchased shares will be the same as the per-share purchase price payable by the underwriter to the Selling Stockholders. IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility. The Repurchase is subject to completion of the offering and the satisfaction of other customary conditions.
Goldman Sachs & Co. LLC and Barclays are acting as joint underwriters of the offering.
The offering, including the Repurchase, is expected to close on March 8, 2019, subject to customary closing conditions.
An automatic shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the Securities and Exchange Commission (“SEC”) on May 24, 2017 and became effective upon filing. Before you invest, you should read the registration statement, the prospectus, the accompanying prospectus supplement and other documents IQVIA has made available with the SEC for information about IQVIA and the offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus and the accompanying prospectus supplement may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusfirstname.lastname@example.org; or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; by email: email@example.com; or by telephone: 1-888-603-5847.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190306005217/en/
CONTACT: IQVIA Holdings Inc.
Andrew Markwick, 973-257-7144
Tor Constantino, 484-567-6732
KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT NORTH CAROLINA
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: IQVIA Holdings Inc.
Copyright Business Wire 2019.
PUB: 03/06/2019 06:00 AM/DISC: 03/06/2019 06:01 AM